NCT01206101 - Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2012

Primary Completion Date

June 3, 2013

Study Completion Date

June 3, 2013

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

liraglutide

Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide dose for 52 weeks. Injected subcutaneously(under the skin) once daily.

DRUG

placebo

Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.

Trial Locations (16)

1211

Novo Nordisk Investigational Site, Geneva

8091

Novo Nordisk Investigational Site, Zurich

25030

Novo Nordisk Investigational Site, Besançon

34295

Novo Nordisk Investigational Site, Montpellier

38043

Novo Nordisk Investigational Site, Grenoble

59037

Novo Nordisk Investigational Site, Lille

60612

Novo Nordisk Investigational Site, Chicago

67091

Novo Nordisk Investigational Site, Strasbourg

91010

Novo Nordisk Investigational Site, Duarte

02114

Novo Nordisk Investigational Site, Boston

53792-0001

Novo Nordisk Investigational Site, Madison

T6G 2C8

Novo Nordisk Investigational Site, Edmonton

V5Z 1M9

Novo Nordisk Investigational Site, Vancouver

01307

Novo Nordisk Investigational Site, Dresden

OX3 7LE

Novo Nordisk Investigational Site, Headington

SE5 9RS

Novo Nordisk Investigational Site, London